Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Tango Therapeutics, Inc. (TNGX) had Normalized Income after Taxes of $-45.51M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-45.51M |
|
-- |
|
-- |
|
$48.77M |
|
$-48.77M |
|
$3.26M |
|
$-45.51M |
|
$-45.51M |
|
$-45.51M |
|
$-45.51M |
|
$-45.51M |
|
|
Normalized Income after Taxes |
$-45.51M |
$-48.77M |
|
$-49.43M |
|
143.58M |
|
143.58M |
|
$-0.32 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$392.33M |
|
$6.38M |
|
$43.47M |
|
$435.79M |
|
$14.33M |
|
-- |
|
$29.96M |
|
$44.29M |
|
$391.51M |
|
$391.51M |
|
$391.51M |
|
144.16M |
|
| Cash Flow Statement Financials | |
$-44.36M |
|
$9.63M |
|
$79.85M |
|
$114.85M |
|
$159.97M |
|
$45.12M |
|
$10.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-44.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.63% |
|
-11.63% |
|
-10.44% |
|
-11.63% |
|
$2.72 |
|
$-0.31 |
|
$-0.31 |
|